Prognostic significance of tumor necrosis factor receptor in colorectal adenocarcinoma

Anticancer Research

Volumn 23, Issue 1 A, 2003, Pages 85-89

  Yoshimura, Hiroshi ^a   Dhar, Dipok Kumar ^a   Nakamoto, Takeru ^a   Kotoh, Tsukasa ^b   Takano, Masahiro ^b   Soma, Gen Ichiro ^c   Nagasue, Naofumi ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b TAKANO HOSPITAL   (Japan)

^c TOKUSHIMA BUNRI UNIVERSITY   (Japan)

Author keywords

Colorectal adenocarcinoma; Tumor necrosis factor; Tumor necrosis factor receptor

Indexed keywords

FORMALDEHYDE; KI 67 ANTIGEN; PARAFFIN; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE FIXATION; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; AGED; ANTIGENS, CD; APOPTOSIS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; STAINING AND LABELING; SURVIVAL RATE;

EID: 0037231237     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bazzoni F and Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 334: 1717-1725, 1996.
2. Papadakis K and Targan SR: Tumor necrosis factor: Biology and therapeutic inhibitors. Gastroenterology 119: 1148-1157, 2000.
3. Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R and Nagasue N: Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res 5: 2464-2469, 1999.
4. Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K and Nakano H: The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 30: 413-421, 1999.
5. Koomagi R and Volm M: Expression of Fas (CD95/APO-1) and Fas Iigand in lung cancer, its prognostic and predictive relevance. Int J Cancer 84: 239-243, 1999.
6. Nagaki M, Naiki T, Brenner DA, Osawa Y, Imose M, Hayashi H, Banno Y, Nakashima S and Moriwaki H: Tumor necrosis factor alpha prevents tumor necrosis factor receptor-mediated mouse hepatocyte apoptosis, but not fas-mediated apoptosis: role of nuclear factor-kappaB. Hepatology 32: 1272-1279, 2000.
7. Creasey AA, reynolds MT and Laird W: Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res 46: 5687-5690, 1986.
8. Kemeny N, Childs B, Larchian W, Rosado K and Kelsen D: A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 66: 659-663, 1990.
9. Fukushima Y, Tanizaki E, Takagi K, Takano M and Soma G-I: Inducibility of endogenous tumor necrosis factor by tumor cells from colorectal tumor patients at Dukes' stage C as a novel prognostic factor following curative operation. Dis Colon Rectum 38: 1059-1066, 1995.
10. Takagi K, Tomita K, Fukushima Y, Chikamoto A, Kanou J, Honda T, Yoshimura H, Nozaki R, Tashiro K and Soma G-I: Endogenous TNF inducibility and prognosis of colorectal cancer. Anticancer Res 18: 4141-4146, 1998.
11. Yoshimura H, Chikamoto A, Honda T, Tashiro K, Nakamoto T, Takano M, Takagi K, Nagasue N and Soma G-I: Relationship between microvessel quantification and inducibility of endogenous tumor necrosis factor in colorectal adenocarcinoma. Anticancer Res 20: 629-634, 2000.
12. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD and Balkwill FR: Expression of tumor necrosis factor (TNFa) and its receptors in benign and malignant breast tissue. Int J Cancer 56: 777-782, 1994.
13. Vinante F, Rigo A, Tecchio C, Morosato L, Nadali G, Ricetti MM, Krampera M, Zanolin E, Locatelli F, Gallati H, Chilosi M and Pizzolo G: Serum levels of p55 and p75 soluble TNF receptors in adult acute leukemia at diagnosis: correlation with clinical and biological features and outcome. British Journal of Haematology 102: 1025-1034, 1998.
14. Tran TA, Kallakury BS, Ambros RA and Ross JS: Prognostic significance of tumor necrosis factors and their receptors in non-small cells lung carcinoma. Cancer 83: 276-282, 1998.
15. Busch C, malmstrom PU, Norlen BJ, Sallstrom J, Brodin T and Lundblad A: A grading system for the immunostaining of A, B and H group isoantigens in bladder carcinoma. Anticancer Res 8: 81-88, 1988.
16. Gavrieli Y, Sherman Y and Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1992.
17. Kaplan EL and Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
18. General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. 6th ed. Tokyo: Japanese Research Society for Cancer of the Colon and Rectum, 1998.
19. Schller JH and Bittner G: Anti-proliferative effects of tumor necrosis factor, gemma interferon, and 5-fluorouracil on human colorectal carcinoma cell lines. Int J Cancer 46: 61-66, 1990.
20. Heim ME, Siegmund R, Illigen HJ, Klee M, Rieche K, Bardel WE and Edler L: Tumor necrosis factor in advanced colorectal cancer: a phase II study. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie 13: 444-447, 1990.
21. Skillings J, Wierzbicki R, Eisenhauer E, Venner P, Letendre F, Stewart D and Weinerman B: A phase II study of recombinant tumor necrosis actor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Immunother 11: 67-70, 1992.
22. Sherwood ER, Pitt Ford TR, Lee C and Kozlowski JM: Therapeutic efficacy, of recombinant tumor necrosis factor alpha in an experimental model of human prostatic carcinoma. J Biol Response Mod 9: 44-52, 1990.
23. Lienard D, Lejeune FJ and Ewalenko P: In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 16: 234-240, 1992.
24. Naylor MS, Stamp GWH, Foulkes WD, Eccles D and Balkwill FR: Tumor necrosis factor and its receptors in human ovarian cancer. J Clin Invest 91: 2194-2206, 1993.
25. Pang XP, Ross NS and Hershman JM: Alterations in TNF-alpha signal transduction in resistant human papillary thyroid carcinoma cells. Thyroid 6: 313-317, 1996.
26. Ocvirk J, Stabuc B, Rudolf Z, Galvani V and Curin-Serbec V: Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients. Melanoma Res 10: 253-258, 2000.